Lee McCracken Net Worth

Lee McCracken biography

Lee Roy McCracken is an Independent Director of the Company. Mr. McCracken has served on our board of directors since October 2015. Mr. McCracken currently is the Chief Executive Officer and a member of the board of directors of Drawbridge Health, Inc., a company focused on enabling personal diagnostic testing, positions he has held since June 2017. From May 2016 to May 2017 and from April 2013 to March 2014, he served as a strategic and restructuring consultant in the regenerative medicine and diagnostic sectors for McCracken Consulting, a consulting firm he founded. Between April 2014 and May 2016, Mr. McCracken was Chief Executive Officer of Gensignia Life Sciences, Inc., a molecular diagnostics company. Earlier in his career, Mr. McCracken held a number of executive positions or roles with significant responsibility at several biotechnology and therapeutics companies, including Pathwork Diagnostics, Inc., Prometheus Laboratories Inc., GenStar Therapeutics Corporation, CombiChem Inc., and Allergan Inc., as well as at the investment companies, 3i Capital and Union Venture. Mr. McCracken received his M.B.A. from the Anderson School of Management at the University of California, Los Angeles, his Master of Computer Science (MCS) from the University of Dayton, and his B.S. in Commerce from Santa Clara University. Our board of directors believes Mr. McCracken’s extensive executive and industry experience and his broad knowledge of molecular diagnostics qualify him to serve on our board of directors.

How old is Lee McCracken?

Lee McCracken is 62, he's been the Independent Director of HTG Molecular Diagnostics Inc since 2015. There are 5 older and 11 younger executives at HTG Molecular Diagnostics Inc. The oldest executive at HTG Molecular Diagnostics Inc is Harry George, 71, who is the Independent Director.

What's Lee McCracken's mailing address?

Lee's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON, AZ, 85706.

Insiders trading at HTG Molecular Diagnostics Inc

Over the last 10 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo, and Laurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.

What does HTG Molecular Diagnostics Inc do?

about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.

HTG Molecular Diagnostics Inc executives and stock owners

HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include:

• John Lubniewski,
  President, Chief Executive Officer, Director
• John L. Lubniewski,
  Pres, CEO & Director
• Shaun D. McMeans,
  Sr. VP, CFO, Sec. & Treasurer
• Shaun McMeans,
  Chief Financial Officer, Senior Vice President, Treasurer, Secretary
• Byron T. Lawson,
  Sr. VP & Chief Commercial Officer
• Timothy Johnson,
  Executive Chairman of the Board
• Byron Lawson,
  Senior Vice President and Chief Commercial Financial Officer
• Lee McCracken,
  Independent Director
• James LaFrance,
  Independent Director
• Donnie Hardison,
  Independent Director
• Michelle Griffin,
  Independent Director
• Harry George,
  Independent Director
• Ann Hanham,
  Lead Independent Director
• Laura Beggrow,
  Pres of Diagnostics
• Dr. Stephen A. Barat Ph.D.,
  Sr. VP of Therapeutics
• Dr. Marian Navratil Ph.D.,
  Sr. VP of R&D
• Dr. Patrick C. Roche,
  Sr. VP of R&D
• Dr. Debra A. Gordon,
  Sr. VP & Chief Legal Counsel
• Laura Lee Godlewski,
  Sr. VP of Fin. & Admin.
• Dr. Maureen T. Cronin Ph.D.,
  Sr. VP & Chief Scientific Officer
• Christopher P Kiritsy,
  Director
• Stephen Barat,
  Senior VP of Therapeutics
• Debra A Gordon,
  V.P. and Chief Legal Counsel
• Lewis Shuster,
  Director
• Plc Gsk,
  10% owner
• Don M Hardison,
  Director
• Holdings A/S Novo,
  10% owner
• Nv Qiagen,
  10% owner
• Patrick C. Roche,
  SVP Research & Development
• Spaght Ventures Ii Lpfsv Ii...,
  
• Donald W Grimm,
  Director
• Capital Ventures Llc Senour...,
  
• Tim B Johnson,
  Executive Chairman
• Laurence W Lytton,
  10% owner
• Thomas W. Dubensky,
  Director
• Laura Lee Godlewski,
  SVP Finance & Administration